Today: 21 July 2026
Browse Category

Pharmaceuticals 11 October 2025 - 21 October 2025

Minerva Neurosciences Stock Skyrockets on $200M Lifeline for Schizophrenia Drug

Minerva Neurosciences Stock Skyrockets on $200M Lifeline for Schizophrenia Drug

Minerva Neurosciences’ stock chart went vertical on Tuesday after the biotech announced an expansive financing deal that effectively triples the company’s market capitalization overnightmarketbeat.com. In pre-market trading on Oct. 21, NERV stock jumped as much as 160% on the newsgurufocus.com. The shares opened around $6–7 and oscillated near those levels through the day, ultimately marking a 52-week high of $6.97marketbeat.com. By comparison, NERV had traded as low as $1.15 within the past yearmarketbeat.com, reflecting both the dramatic rebound and the extreme volatility inherent in this micro-cap biotech.
21 October 2025
··
iBio Stock Surges on Bullish Analyst Calls and Obesity Drug Breakthroughs

iBio Stock Surges on Bullish Analyst Calls and Obesity Drug Breakthroughs

As of midday October 21, 2025, iBio’s stock trades around $0.89 per sharemarketbeat.com. The price has been volatile in recent days. Last week, shares jumped over 20% in pre-market trading on October 17 after Leerink Partners issued a bullish initiation, although the stock later settled near $0.85 by that day’s closemarketbeat.com. Even with these upticks, iBio’s stock remains well below its levels earlier this year – it began 2025 at ~$2.45 and has declined about 63% year-to-datemarketbeat.com. This underperformance comes amid broader small-cap biotech volatility; by comparison, the biotech sector ETF is up roughly 20% in 2025finance.yahoo.com. iBio’s modest market capitalization and thin trading volume reflect its micro-cap statusmarketbeat.comreuters.com, which can magnify price swings on news.
21 October 2025
·
SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

stockanalysis.com stockanalysis.com Spero’s shares have roughly doubled this year, hitting around $2.29 on Oct 20, 2025. The stock has traded in a broad range stockanalysis.com. Trading volume is light, and the stock’s beta indicates volatility. In recent days, SPRO has climbed on the back of the Phase 3 data. The 50-day moving average and 200-day average suggest the trend has turned positive after the spring rally. Year-to-date, SPRO is up ~120%, well above the small-cap biotech average.
21 October 2025
···
AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

Recursion Pharma Stock Soars 16% on AI Buzz and Big Pharma Deals – Can RXRX Keep Climbing?

Recursion’s stock is on a rollercoaster ride this month. Early on October 20, RXRX surged ~16–18%, hitting intraday highs near $6.8benzinga.com. The rally comes after shares slid 7.9% on Friday to $5.86stockinvest.us, as traders took profits following a mid-October run-up. Broader market tailwinds helped – the Nasdaq Composite was up ~1% on Monday – and several biotech peers also soared on newsbenzinga.com. Recursion’s sharp rebound Monday recoups some losses from last week’s pullback and underscores the extreme volatility surrounding this AI-driven biotech.
20 October 2025
··
Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Before the late-September rally, Pfizer’s stock had been trading lethargically. As one analysis notes, PFE closed around $23.60 on Sept. 26, roughly flat for the year and down ~9% since January ts2.tech. Over the prior 12 months it had fallen about 18%, weighed down by fading COVID sales and patent losses ts2.tech. Its 52-week range was about $20.9–$30.4 ts2.tech, so the recent surge took it to the upper end of that range.
19 October 2025
·
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics, a clinical-stage biotech developing the RaniPill® capsule for oral delivery of biologic drugs, was essentially flat around $0.45–$0.50 from mid-September through early October. On Oct. 17, it announced a collaboration with Chugai to turn one of Chugai’s injectable rare-disease antibodies into a pill formulation. The news, coupled with the new funding, ignited a buying frenzy ts2.tech. By mid-day Friday, RANI was up ~180% on the session ts2.tech, markedly outpacing the broader market’s modest gains.
18 October 2025
···
Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences Stock Soars on Patent Win and HIV Breakthroughs – Will the Rally Continue?

Gilead’s stock has been on a tear in recent weeks, far outpacing the broader market. After trading in the high $110s earlier in October, GILD spiked 4.2% on Friday, Oct. 17, to close at $122.81stockanalysis.comstockanalysis.com. That rally marked a new 2025 high for the biotech stalwart and brings its year-to-date gain to roughly 45–47%ts2.tech. By comparison, the Nasdaq Biotechnology Index is up only in the single digits over the same periodts2.tech. The recent jump – adding billions to Gilead’s market cap – reflects mounting investor enthusiasm driven by a confluence of positive news. “Investors have cheered a string of positive catalysts: strong earnings, a fortified HIV franchise, and growing pipeline prospects,” TechStock² noted in an analysists2.tech.
18 October 2025
···
XORTX Therapeutics (XRTX) Stock Skyrockets on Kidney Drug Deal – Key Facts & Outlook

XORTX Therapeutics (XRTX) Stock Skyrockets on Kidney Drug Deal – Key Facts & Outlook

Shares of XORTX Therapeutics Inc. surged on October 17, 2025 after the nano-cap biotech announced a strategic acquisition in its core therapeutic area. The stock rocketed up immediately following the morning press release, spiking up to 40% in early trading. By midday, XRTX was changing hands at just over $1.20 per shareragingbull.com. It eventually closed about 21% higher on Fridaytipranks.com – a dramatic move for a company that had been trading quietly near the $1 level.
17 October 2025
·
Weight-Loss Drug Mania Shook Markets—Now Hims & Hers Bets on a Menopause Care Boom

Weight-Loss Drug Mania Shook Markets—Now Hims & Hers Bets on a Menopause Care Boom

Hims & Hers’ expansion into menopause care was greeted with enthusiasm in the market. On October 15, the San Francisco–based telehealth provider announced it is now offering affordable treatment plans for women in perimenopause and menopause via its Hers platform businesswire.com businesswire.com. The move adds a new specialty to Hers, which already serves over 500,000 women subscribers businesswire.com. By connecting patients with providers trained in menopause care, Hims & Hers aims to fill a long-neglected gap in women’s health. “Women have been navigating an outdated healthcare system that wasn’t designed for them for too long. Hers was built to serve every woman on her terms,” said Dr. Jessica Shepherd, Chief Medical Officer of Hims & Hers businesswire.com businesswire.com. She noted that the goal is “building a platform that women can trust to access the care they need,” by increasing access to specialists for every life stage businesswire.com.
17 October 2025
·
Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Rani Therapeutics’ stock price skyrocketed on Friday, Oct. 17, after the company unveiled a major partnership and funding news. In pre-market trade, RANI jumped about 150% and continued to rally after the market open tipranks.com. The stock, which had closed at just $0.47 the prior day, briefly hit approximately $1.37 per share – nearly a 3× gain in value google.com. By midday, shares were still trading around the $1.30 level, up almost +180% on the day. This stunning one-day move snapped RANI out of penny-stock territory and back above the Nasdaq’s $1 minimum bid price, easing near-term delisting fears.
17 October 2025
···
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Surges on Obesity Drug Boom and Alzheimer’s Breakthroughs – Is $1,000 Next?

Eli Lilly’s stock has been on a tear in 2025, powered by optimism around its new drug innovations. Shares surged dramatically at the start of October – leaping from about $726 at the end of September to as high as $832 by October 1ts2.tech. This double-digit jump in just days far outpaced the broader market and reflected euphoric sentiment toward Lilly’s growth prospectsts2.tech. Analysts attributed the rally to a perfect storm of positive news: strong recent earnings, insider buying, and fresh research fueling excitement about Lilly’s obesity and Alzheimer’s franchisests2.tech. For example, one study in late September suggested GLP-1 weight-loss drugs may significantly reduce Alzheimer’s risk, adding to the buzz around Lilly’s pipelinets2.tech.
17 October 2025
··
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s Weight-Loss Crown at Risk? NVO Stock Slumps Amid Surprise Deals – What’s Next

Novo Nordisk’s stock has been on a wild ride. After becoming Europe’s most valuable company in 2022–2023 on the back of its smash-hit obesity drug Wegovy, the Danish pharma giant has seen its fortunes reverse sharply in 2025. As of October 17, NVO shares trade in the mid-$50s – down nearly 50% from January levelsreuters.comreuters.com and miles below the late-2024 peakreuters.comreuters.com. What happened? In short, the once-unbounded GLP-1 weight-loss boom has hit reality.
17 October 2025
··
Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

Praxis Precision Medicines stock has seen a record-breaking spike in recent days after announcing landmark clinical trial results. On October 16, PRAX shares closed at $162.71, up about 183% in a single session ts2.tech ts2.tech. The stock, which had closed at $57.35 the day prior, more than tripled to reach new 52-week highs ts2.tech. Intra-day, PRAX briefly touched as high as $205 as enthusiasm peaked google.com. By midday Thursday, the company was on track to add roughly $2.7 billion to its market capitalization if gains held ts2.tech – catapulting Praxis’s valuation from around $1 billion to nearly $4 billion overnight. The explosive rally continued into Friday, Oct. 17: shares gained another ~5% in post-market and pre-market trading stocktwits.com as Wall Street’s reaction grew increasingly bullish.
17 October 2025
··
Scienture (SCNX) Stock Skyrockets on New FDA-Approved Blood Pressure Drug Launch

Scienture (SCNX) Stock Skyrockets on New FDA-Approved Blood Pressure Drug Launch

Pills and a daily pill organizer: Arbli’s liquid formulation helps patients who can’t swallow tablets. Scienture’s stock jumped sharply on Oct. 16 after the company formally launched Arbli™ in the U.S. market. In a GlobeNewswire press release that morning, Scienture announced that Arbli™ is now shipping through major pharmaceutical wholesalers nationwideglobenewswire.com. Arbli is the first FDA-approved oral liquid form of losartan, a top-selling blood pressure drug. The launch news and accompanying marketing caused traders to bid up SCNX: one trader wrote that shares moved “from yesterday’s close around 72 cents to nearly 95 cents” on the newsragingbull.com. By mid-day, Reuters reported SCNX trading near $0.71, up ~30% from the prior closereuters.com.
16 October 2025
··
Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?

Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?

Adaptimmune’s stock has been on a wild ride this year, with extreme price swings in recent weeks grabbing headlines. After languishing in penny-stock territory for months, ADAP suddenly caught fire in late September 2025. On September 19, shares opened at a mere $0.08 but skyrocketed 98% by day’s end to $0.16, then jumped another 30% after-hours to ~$0.20 ts2.tech. This stunning one-day move – without any company-specific catalyst – was accompanied by an enormous volume of 705+ million shares traded ts2.tech. Market observers noted Adaptimmune as one of the top gainers that session despite the lack of fundamental news nasdaq.com ts2.tech. The rally appeared driven by renewed investor interest and speculation, not new data – a Nasdaq report bluntly stated “no company-specific news was released on September 19” to explain the surge nasdaq.com. Instead, retail traders and momentum algorithms seemed to pile in, possibly in a short-squeeze frenzy or simple fear of missing out.
16 October 2025
··
Menopause Launch Sends Hims & Hers (HIMS) Stock Soaring – What’s Next?

Menopause Launch Sends Hims & Hers (HIMS) Stock Soaring – What’s Next?

On Oct. 15, Hims & Hers stunned the market by launching a dedicated menopause/perimenopause care program on its “Hers” telehealth platform. The company said the new service would connect women with personalized hormone therapies to ease symptoms like hot flashes and sleep issuests2.tech. This push into a historically underserved sector met eager investor demand. As Benzinga and TS2.tech reported, HIMS stock raced +10–13% that day, trading near $60 with extremely heavy volumets2.tech. By the close, HIMS was up roughly +16%, a one-day gain not seen in monthsts2.techts2.tech.
16 October 2025
··
AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

AbbVie’s stock closed at $230.88 on Oct. 10, 2025marketbeat.com. Over the prior five trading days it moved modestly: Oct. 7: $232.83; Oct. 8: $231.24; Oct. 9: $230.69; Oct. 10: $230.50investing.com. Notably, on Sept. 30 ABBV hit a 52-week high around $244.8, buoyed by regulatory filings and a sector-wide rally. From that late-September peak it has pulled back into the low-$230s as investors digest upcoming FDA news. On Oct. 1 the entire pharma sector rallied after Pfizer announced a U.S. drug-pricing dealreuters.com; AbbVie’s shares jumped ~6–8% that day as well. Technicals remain bullish, and the stock trades above bothmarketbeat.com, though momentum indicators suggest it could be oversold.
11 October 2025
··
AstraZeneca (AZN) Stock Skyrockets: $50B U.S. Gamble, Trump Pricing Deal & Analyst Forecasts

AstraZeneca (AZN) Stock Skyrockets: $50B U.S. Gamble, Trump Pricing Deal & Analyst Forecasts

AstraZeneca PLC is a leading Anglo-Swedish pharmaceutical giant specializing in oncology, respiratory, cardiovascular/metabolic, and rare disease medicinesmarketbeat.comastrazeneca.com. Headquartered in Cambridge, UK, it maintains primary listings on the London Stock Exchange and Nasdaq Stockholm, with secondary ADR trading in the U.S.astrazeneca.com. The company was formed in 1999 by merging Sweden’s Astra AB and the UK’s Zeneca. Its 2024 revenues were $54.07 billionastrazeneca.com, driven by top-selling drugs like Tagrisso, Lynparza, Farxiga, and Symbicortmarketbeat.com. In its 2024 Annual Report, AZN describes itself as “a global, science-led, patient-focused pharmaceutical business” and targets $80B in sales by 2030 with at least 20 new drugs launchedastrazeneca.comastrazeneca.com. Current Chair Michel Demaré and CEO Sir Pascal Soriot lead a company with roughly 70–80,000 employees worldwide, strategic R&D hubs in the US, UK, Sweden, China and emerging cell/gene therapy centers.
11 October 2025
···
Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Merck & Co. is a global healthcare company organized in Pharmaceuticals, Vaccines and Animal Health. It focuses on oncology/immunology, infectious disease, cardio-metabolic, and hospital specialty medicinesmerck.com. Its blockbuster product KEYTRUDA® – a PD-1 checkpoint inhibitor – has driven Merck’s growth, accounting for >50% of pharma sales in H1 2025nasdaq.com. Other pillars include GARDASIL® and type-2 diabetes drugs. Merck invests heavily in R&D, with hundreds of projects in clinical development. In mid-2025 the company announced a transformation plan to reallocate resources toward “new growth drivers” – including acquisitions and upcoming product launches – to drive long-term innovationmerck.com.
11 October 2025
··
Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Protagonist Therapeutics is a clinical-stage biopharma company leveraging peptide technology to create new medicines for rare hematologic conditions and prevalent immunological diseasesprotagonist-inc.com. Founded in 2008, Protagonist has built its identity around engineered peptide drugs – a niche between small molecules and antibodies – to tackle challenging targets with oral or injectable therapies. The company’s mission centers on “developing groundbreaking new medicines to treat both rare and prevalent diseases” using its proprietary peptide platformprotagonist-inc.com. This focus has led to a pipeline addressing blood cancers/disorders and inflammatory bowel and skin diseases, where current treatments are inadequate.
11 October 2025
·····
1 … 40 41 42 43 44
Go toTop